SCHEMBL8005582

SCHEMBL8005582

Cn1c(-c2ccc(F)c(F)c2)nc(-c2ccc(C(C)(C)O)nc2)c1Sc1ccc(Cl)cc1F

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.44
KCNH2 Q12809 2/20 0.44
PTGS2 P35354 3/20 0.35
PTGS1 P23219 1/20 0.33
TRPV3 Q8NET8 1/20 0.33
SYK P43405 4/20 0.32
GABRA1 P14867 4/20 0.32
GABRG2 P18507 4/20 0.32
GABRB3 P28472 4/20 0.32
GABRA5 P31644 4/20 0.32
GABRA3 P34903 4/20 0.32
GABRA2 P47869 2/20 0.32
TGFBR1 P36897 1/20 0.32
USP2 O75604 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
HSD17B10 Q99714 1/20 0.31
COMT P21964 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12106792 0.93 FAAH (0.50) FAAHKCNH2TRPV3SYKGABRA1
SCHEMBL12107035 0.89 FAAH (0.43) FAAHKCNH2TRPV3SYKGABRA1
SCHEMBL12106796 0.89 FAAH (0.48) FAAHKCNH2PTGS2PTGS1TRPV3
SCHEMBL8003103 0.87 FAAH (0.52) FAAHKCNH2PTGS2PTGS1TRPV3
SCHEMBL12106801 0.79 FAAH (0.53) FAAHKCNH2PTGS2PTGS1SYK
SCHEMBL8004716 0.78 FAAH (0.46) FAAHKCNH2PTGS2SYKGABRA1
SCHEMBL12106789 0.77 FAAH (0.53) FAAHKCNH2PTGS2PTGS1TRPV3
SCHEMBL1004255 0.75 FAAH (0.73) FAAHKCNH2GABRA1GABRG2GABRB3
SCHEMBL7993150 0.75 FAAH (0.54) FAAHKCNH2PTGS2SYKGABRA1
SCHEMBL12107044 0.74 FAAH (0.48) FAAHKCNH2TRPV3SYKGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
WO-2009152025-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK & CO., INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH FAAH, FAAH2, HNMT FAAH 1/4885KCNH2 1076/4885PTGS2 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.